Skip to main content

Change location

You are currently on the Poland (English) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Poland (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

        • Iomeron
      • Medical devices

        • CT Exprès
        • Empower CTA+
    • MRI
      • Contrast agents

        • MultiHance
        • ProHance
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • Sonovue
    • Nuclear medicine
    • Interventional cardiology
      • Contrast agents

        • Iomeron
        • Iomeron 400
      • Medical devices

        • ACIST CVi
        • ACIST HDi
        • ACIST RXi
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Events
  • Ceriano Laghetto
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
  1. Home
  2. Our Portfolio
  3. Interventional cardiology
  4. Medical devices

  5. ACIST HDi

Bottle of medicine

ACIST HDi

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Iaculis adipiscing habitasse tempus et pellentesque quisque. Viverra feugiat massa enim vulputate neque, eget pretium. Id vitae gravida eros, dictumst auctor amet quis id. Morbi nisl amet velit pellentesque vitae fermentum tempor ultricies vitae. Lacus, varius lobortis nunc ut adipiscing. Enim in semper a cras. Lectus nisl, sit diam porttitor at molestie.

The active ingredient of MultiHance® (gadobenate dimeglumine, or Gd-BOPTA) possesses an aromatic (benzyloxymethyl) group on the contrast-effective molecule.

 

 

Image placeholder

 

 

Thanks to its chemical structure, Gd-BOPTA is actively transported into functioning hepatocytes, and up to 4% of the injected dose is excreted via the hepatobiliary route into the bile and, ultimately, the faeces.2, 3, 4

 

In view of its pharmacokinetics, MultiHance® can be used both for dynamic and delayed, liver-specific imaging in adult and pediatric patients. Evidence shows that:

 

  • Dynamic imaging is not affected by short-term dyspnea and respiratory motion artifacts.5,6,7
  • Delayed, liver-specific imaging offers extended opportunities for the assessment of focal liver lesions, with further increase in sensitivity and specificity for detection and characterization of liver disease over and above those provided by dynamic imaging when images are acquired 40-120 minutes after injection of the agent.8,9,10,11

 

Therefore, MultiHance® should be used when diagnostic information is essential and not available with unenhanced MRI and when delayed phase imaging is required.

 

The aromatic group on Gd-BOPTA also provides increased r1-relaxivity relative to that of the macrocyclic GBCAs12, 13, 14, 15 and hence greater signal intensity (SI) enhancement on T1-weighted images16. This is why MultiHance® allows both dynamic and delayed, organ-specific imaging of the liver at a dose as low as 0.05 mmol/kg.

 

Therefore, the recommended dose of MultiHance® in adult patients and children is 0.05 mmol/kg body weight (0.1 mL/kg of the 0.5 M solution). The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient’s body weight, and should not exceed the recommended dose per kilogram of body weight.1The safety of MultiHance® has been established in numerous clinical investigations and during extensive clinical use with 35 million doses administered worldwide since its launch.17,18,19,20

 

The safety of MultiHance® has also been studied in children and in special populations, such as children and patients with impairment of renal and/or liver function.21,22,23,24,25,26,27,28,29,30,31,32

Image placeholder
(Place logo here)

Lorem ipsum dolor sit "brand name"

 

Visit microsite

DISCLAIMER

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Iaculis adipiscing habitasse tempus et pellentesque quisque. Viverra feugiat massa enim vulputate neque, eget pretium. Id vitae gravida eros, dictumst auctor amet quis id. Morbi nisl amet velit pellentesque vitae fermentum tempor ultricies vitae. Lacus, varius lobortis nunc ut adipiscing. Enim in semper a cras. Lectus nisl, sit diam porttitor at molestie.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Iaculis adipiscing habitasse tempus et pellentesque quisque. Viverra feugiat massa enim vulputate neque, eget pretium. Id vitae gravida eros, dictumst auctor amet quis id. Morbi nisl amet velit.

Please login to DocCheck
to view our products

Register here Forgot your password?

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Pharmacovigilance
  • Data Protection

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182